Renal cell cancer

Renal cell cancer

  • April 2016 •
  • 283 pages •
  • Report ID: 4035409 •
  • Format: PDF
Despite the approvals of several pipeline therapies, the renal cell cancer (RCC) market is expected to experience only moderate growth due to market saturation and the expiries of key brand patents.

This report addresses the following questions:

- What factors are contributing to the increase in RCC incidence across the US, Japan, and five major EU markets?
- What impact will the entry of PD-1 inhibitor Opdivo have on the RCC market?
- When are pipeline therapies in development for RCC expected to gain approval and what is their commercial outlook?
- How will genericization of key brands impact the overall value of the RCC market?
- Which treatment settings represent attractive targets for drug developers?
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.